The company successfully commissioned an expanded manufacturing facility, increasing NexoBrid production capacity sixfold to meet anticipated global demand.
Revenue for 2025 was impacted by the U.S. government shutdown, which delayed budget approvals and the initiation of new development service contracts.
The Phase III VALUE trial for EscharEx in venous leg ulcers (VLU) is advancing as planned, with the majority of clinical sites now active and enrolling.
Strategic expansion of the EscharEx program into diabetic foot ulcers (DFU) and pressure ulcers aims to capture the three major chronic wound indications.
Gross margin improvement in 2025 was driven by a more favorable revenue mix despite lower overall top-line results.
Management maintains operational resilience and discipline in Israel despite ongoing regional conflict, ensuring clinical and commercial milestones remain on track.
Industry validation continues to grow through research collaborations with seven market-leading wound care companies, including a new partnership with B. Braun.
Revenue guidance of $24 million to $26 million for 2026 assumes regulatory approval of the expanded manufacturing facility and resumed BARDA/DOW support.
The 2028 revenue target of $50 million to $55 million includes the first potential commercial contributions from EscharEx, subject to regulatory approval.
Management expects to complete the EscharEx Phase III VALUE trial enrollment and conduct a prespecified interim assessment by year-end 2026.
Future growth strategy prioritizes national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems.
The company plans to initiate a Phase II study in diabetic foot ulcers and an investigator-initiated study in pressure ulcers during 2026.
The U.S. government shutdown served as a primary headwind in 2025, causing a $7.0 million revenue shortfall compared to initial expectations.
A $30.0 million registered direct offering and warrant exercises strengthened the balance sheet to $53.6 million in cash at year-end.
R&D expenses increased significantly to $14.0 million in 2025, reflecting the intensified investment required for the EscharEx Phase III program.
Commercial release of product from the new manufacturing site is contingent upon regulatory approvals expected in 2026.
Capacity has increased sixfold, but commercial output from the new site is subject to regulatory approvals expected in late 2026.
Management noted that current demand across territories exceeds current manufacturing capabilities, though they have guided conservatively based on expected clearance timelines.
finance.yahoo.com
#MediWound #Earnings #Call #Summary
